Potential 'Mega-Blockbuster' Bimzelx Heading For Psoriasis Market In UK & EU
Reimbursement Talks Under Way In European Countries
Executive Summary
Bimzelx, which is expected to make a big splash in the psoriasis market, received its two marketing authorizations just days apart.
You may also be interested in...
US FDA’s October Outlook Includes Psoriasis Blockbuster Hopeful, Ophthalmology And Orphans
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.
UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.
UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.